{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:48Z","timestamp":1791090648865,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.tvjl.2011.01.001","type":"journal-article","created":{"date-parts":[[2011,2,19]],"date-time":"2011-02-19T10:02:41Z","timestamp":1298109761000},"page":"131-134","source":"Crossref","is-referenced-by-count":24,"title":["Masitinib as a chemosensitizer of canine tumor cell lines: A proof of concept study"],"prefix":"10.1016","volume":"191","author":[{"given":"D.H.","family":"Thamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2011.01.001_b0005","first-page":"315","article-title":"Role of mast cells in tumor growth","volume":"37","author":"Conti","year":"2007","journal-title":"Annals of Clinical and Laboratory Science"},{"key":"10.1016\/j.tvjl.2011.01.001_b0010","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tvjl.2011.01.001_b0015","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1593\/neo.08636","article-title":"PI3K\/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate towards sarcoma cells","volume":"10","author":"Elia","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.tvjl.2011.01.001_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2011.01.001_b0025","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2460\/ajvr.71.11.1354","article-title":"Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors","volume":"71","author":"Hahn","year":"2010","journal-title":"American Journal of Veterinary Research"},{"key":"10.1016\/j.tvjl.2011.01.001_b0030","doi-asserted-by":"crossref","first-page":"e9430","DOI":"10.1371\/journal.pone.0009430","article-title":"Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model","volume":"5","author":"Humbert","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tvjl.2011.01.001_b0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tvjl.2011.01.001_b0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00280-010-1299-8","article-title":"Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"66","author":"Mitry","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023311000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023311000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T17:53:10Z","timestamp":1543945990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023311000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1090023311000049"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2011.01.001","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}